Association Between Serum Uric Acid Level and Components of the Metabolic Syndrome  by Lin, Shi-Dou et al.
Introduction
Cardiovascular disease has been suggested to be asso-
ciated with increased serum uric acid (UA) level1–3
and an increased number of the components that
contribute to metabolic syndrome.4 There is also an
established link between serum levels of UA and indi-
vidual risk factors such as hypertension5 or dyslipi-
demia6,7 that increase cardiovascular risk. However,
the association between an increasing number of meta-
bolic components and serum UA has not been well
studied except for 2 previous studies in the West.4,8
We sought to determine the association between serum
UA and the number of risk factors that contribute to
the metabolic syndrome, and which factor is associ-
ated most with higher serum UA level in a cohort of
hospital staff in a medical center in Taiwan.
Methods
This was a cross-sectional study of a consecutive sam-
ple of 3,065 staff who underwent health examination
between January 2004 and December 2004 at a med-
ical center in Taiwan. Blood tests and all physical vari-
ables were examined at nearly the same time. Blood
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pressure (BP) was measured using an automated sphyg-
momanometer, with the patient in the sitting position
before the blood test. Body mass index (BMI) was
calculated as weight (kg) divided by height squared
(m2). Waist circumference (WC) was measured with
the measuring tape positioned midway between the
lowest rib and the superior border of the iliac crest
while the patient exhaled normally.9
The blood sample was collected in the morning
after an 8–12-hour fast. Levels of glucose, UA, creati-
nine, liver enzymes, total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), and triglyceride
(TG) were determined in the hospital laboratory
using standard methods. The components that con-
tribute to metabolic syndrome were defined as high
BP (≥ 130/85 mmHg), truncal obesity (WC > 90 cm
for men, > 80 cm for women), hypertriglyceridemia
(>150mg/dL or 1.7mmol/L), low HDL-C (<40mg/
dL or 1.0mmol/L for men, < 50mg/dL or 1.3mmol/L
for women) and hyperglycemia (fasting blood glucose
level ≥ 110 mg/dL or 6.1 mmol/L).10 Subjects were
divided into 5 groups according to their possession 
of 0, 1, 2, 3 or ≥ 4 components of the metabolic 
syndrome.
Baseline demographic data in the 5 groups were
descriptively summarized. Continuous variables were
expressed as mean ± standard deviation. Categorical
variables were presented as percentages. The differ-
ences in all variables between groups were compared
using ANOVA. The relationship between serum UA
and increasing number of risk factors was determined
by linear regression analysis. The contribution to ele-
vated serum UA of possessing different risk factors was
determined by a multivariate linear regression model.
Significance was defined as p < 0.05 for all statistical
tests, which were performed using SPSS version 10.0
(SPSS Inc., Chicago, IL, USA) for Windows.
Results
The demographic data of the study cohort are pre-
sented in Table 1. All variables showed significant dif-
ferences between groups, with an increasing trend 
as the number of components increased (except for
HDL-C, which showed a decreasing trend). Mean
serum UA levels increased in subjects who had 0, 1, 2,
3 and ≥ 4 components and demonstrated a significant
linear trend. By linear regression analysis and adjusting
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Table 1. Demographic data of the population based on the number of risk factors*
Number of metabolic risk factors
0 (n = 1,555) 1 (n = 878) 2 (n = 411) 3 (n = 158) ≥ 4 (n = 63)
Variable
Sex (% males) 10.9 25.1 37.0 41.1 44.4
Age (yr) 30.7 ± 7.5 33.8 ± 9.2 36.6 ± 10.2 38.2 ± 10.0 37.7 ± 9.7
BMI (kg/m2) 20.68 ± 2.33 22.69 ± 3.15 25.81 ± 3.62 27.22 ± 3.78 28.91 ± 3.74
WC (cm) 70.80 ± 6.38 77.36 ± 8.75 85.63 ± 8.17 89.57 ± 9.82 93.57 ± 8.94
SBP (mmHg) 108.5 ± 9.2 119.8 ± 13.6 126.2 ± 15.9 129.5 ± 16.5 131.2 ± 15.6
DBP (mmHg) 73.7 ± 6.5 82.1 ± 9.9 86.7 ± 10.1 90.0 ± 11.4 92.4 ± 10.4
FPG (mmol/L) 4.75 ± 0.38 4.92 ± 0.51 5.19 ± 1.12 5.51 ± 1.32 6.29 ± 1.79
UA (μmol/L) 293 ± 68 326 ± 85 362 ± 97 292 ± 100 419 ± 104
Cr (μmol/L) 73 ± 12 77 ± 15 80 ± 18 82 ± 18 82 ± 16
HDL-C (mmol/L) 1.76 ± 0.31 1.58 ± 0.35 1.38 ± 0.34 1.19 ± 0.23 1.04 ± 0.15
TG (mmol/L) 0.70 ± 0.28 0.91 ± 0.44 1.44 ± 0.98 2.12 ± 1.30 2.66 ± 1.09
LDL-C (mmol/L) 2.60 ± 0.65 2.84 ± 0.80 3.19 ± 0.82 3.35 ± 0.77 3.43 ± 0.83
TC (mmol/L) 4.74 ± 0.76 4.86 ± 0.94 5.19 ± 1.00 5.36 ± 0.88 5.44 ± 1.02
AST (IU/dL) 19.8 ± 11.3 20.7 ± 9.5 24.2 ± 14.7 26.5 ± 20.4 33.3 ± 24.9
ALT (IU/dL) 16.7 ± 20.0 20.3 ± 21.0 28.9 ± 28.0 36.2 ± 37.2 50.2 ± 42.1
WBC (×109/L) 5.8 ± 1.5 6.1 ± 1.6 6.6 ± 1.7 6.6 ± 1.6 7.1 ± 1.7
RBC (×1012/L) 4.43 ± 0.42 4.59 ± 0.50 4.76 ± 0.51 4.84 ± 0.49 4.87 ± 0.45
Platelets (×109/L) 255.4 ± 54.5 265.8 ± 60.5 272.8 ± 59.4 287.7 ± 57.9 293.4 ± 64.0
*All variables showed significant differences between groups (p < 0.05). BMI = body mass index; WC = waist circumference; SBP = systolic blood pressure;
DBP = diastolic blood pressure; FPG = fasting plasma glucose; UA = uric acid; Cr = creatinine; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides;
LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; AST = aspartate aminotransferase; ALT = alanine aminotransferase; WBC = white blood cell
count; RBC = red blood cell count.
for other confounding factors (age, BMI, serum crea-
tinine, LDL-C, TC, aspartate aminotransferase, alanine
aminotransferase, white blood cell count, red blood cell
count, platelet number), it was found that men had a
higher serum UA level than women with the same risk
factors, and there were significant differences in UA
levels between groups as the number of risk factors
increased (p < 0.001).
Table 2 lists the mean increased level of UA in
subjects with various components of the metabolic
syndrome after adjusting for confounding variables
with and without BMI. Serum UA level was highest
in subjects with abnormal levels of TG, with a mean
increase in UA level of 22.8 μmol/L compared to
subjects with normal TG. People who had abnormal
WC, HDL-C and BP showed increases in UA levels
of 21.4, 14.4 and 9.4 μmol/L, respectively. Having
an abnormal level of fasting glucose did not affect
serum UA level. After controlling for BMI, which may
be a confounding factor for UA level and is well cor-
related to WC, the apparent influence of abnormal
metabolic components on UA decreased. Abnormal
TG had the greatest effect on UA level, while abnor-
mal HDL-C and BP, in order of influence, were also
associated with elevated UA.
Discussion
This study showed the significant relationships be-
tween serum UA and 5 components of the metabolic
syndrome. As the population with 5 components was
small in our study, this group was combined with
people who had 4 components. We found that serum
UA level was significantly higher and increased in a
linear fashion in subjects who had an increased num-
ber of risk factors; this relationship remained significant
even after controlling for other confounding factors.
This result has also been demonstrated in other stud-
ies.4–8 We further separated subjects into male and
female groups, and found that serum UA level was
higher in men. This result was not unexpected as it is
known that estrogen promotes excretion of UA,11,12
and the mean age of the female cohort was 32.1 years
(range, 30.5–38.6).
Elevated serum UA levels are commonly seen in
association with individual cardiovascular risk factors
such as hypertriglyceridemia,6,13,14 hypertension,5
obesity,6,15 and hyperglycemia,16–18 a cluster that, when
found together in the same person, characterizes the
so-called metabolic syndrome. In our study, abnormal
TG had a stronger association with increasing serum
UA level than all the other components. This finding
is in agreement with other studies,6,13,14 which have
consistently found that TG correlates independently
with UA level. The mechanism for the strong associa-
tion between TG and UA concentrations has not been
elucidated. Although genetic factors are associated with
the concurrence of gout and hypertriglyceridemia,19,20
investigators have generally concluded that hyper-
uricemia and hypertriglyceridemia reflect the lifestyle
of the patient more than genetic factors because obe-
sity is also associated with these characteristics.21
Abnormal HDL-C was also associated with elevated
UA in our study. This is reasonable because serum
UA level correlated negatively with HDL-C in other
studies.22,23 Hyperinsulinemia has been shown to
increase tubular resorption of sodium, with a conse-
quent impairment in the kidney’s ability to excrete
UA.17 So, people with normal glycemia may have
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Table 2. Mean increased level of uric acid, comparing abnormal to normal metabolic components after adjusting for confounding 
variables* with and without body mass index (BMI)
Metabolic factor
All factors except BMI adjusted for All factors adjusted for
Mean (95% CI) p Mean (95% CI) p
Constant 93.3 (56.8–129.8) < 0.001 22.4 (–16.4–61.1) 0.258
AbnTG 22.8 (14.2–31.5) < 0.001 19.8 (11.3–28.4) 0.07
AbnHDL-C 14.4 (6.6–14.1) < 0.001 12.0 (4.3–19.6) 0.002
AbnBP 9.4 (4.0–14.8) 0.001 6.6 (1.2–11.9) 0.016
AbnWC 21.4 (15.3–27.5) < 0.001 2.8 (–4.4–9.9) 0.445
AbnFPG –7.1 (–19.8–5.5) 0.268 –9.2 (–21.7–3.2) 0.146
R2 0.457 0.473
*Confounding variables were sex, age, body mass index, total cholesterol, low-density lipoprotein cholesterol, creatinine, aspartate aminotransferase, alanine
aminotransferase, white blood cell count, red blood cell count, and platelet number. AbnTG = triglycerides > 150 mg/dL or 1.7 mmol/L; AbnHDL-C = high-density
lipoprotein cholesterol < 40 mg/dL or 1.0 mmol/L for men and < 50 mg/dL or 1.3 mmol/L for women; AbnBP = systolic blood pressure ≥ 130 mmHg or dias-
tolic blood pressure ≥ 85 mmHg; AbnWC = waist circumference > 90 cm for men and > 80 cm for women; AbnFPG = fasting plasma glucose ≥ 110 mg/dL or
6.1 mmol/L.
higher UA level if they are more insulin resistant. On
the other hand, hyperglycemia (> 144 mg/dL) with
glucosuria may increase UA excretion,16,18 resulting
in lower serum UA. Since the cut-off point of abnor-
mal fasting glucose in metabolic syndrome is 110 mg/
dL, not representing hyperinsulinemia, it is not surpris-
ing that there was no significant difference in serum
UA level between the normal and abnormal fasting
glucose groups. Insulin resistance is also associated
with higher TG,24 WC,25,26 and lower HDL-C.24
Therefore, it can be proposed that the elevated UA
level in our subjects who had abnormal TG, WC and
HDL-C was due to concomitant higher insulin resist-
ance. The association of higher serum UA level with
higher BP has been reported in other studies.5,27 It
was also found in our study that subjects with abnor-
mal BP had higher UA levels. UA may contribute to
endothelial dysfunction and may play a causal role in
the pathogenesis of hypertension.27 We conclude that
higher BP was associated with higher UA level in our
study, although whether or not high BP accounted
for hyperuricemia is not clear.
It has been suggested that UA may be a cause of the
metabolic syndrome.28 In fructose-fed rats, lowering
UA level prevented or improved most features of the
metabolic syndrome, including the prevention of hyper-
insulinemia, hypertriglyceridemia, hypertension and
weight gain.28 Studies in humans have found that UA
is a potent predictor of hyperinsulinemia29 and weight
gain.30 This is possibly due to its ability to inhibit
endothelial function by impairing nitric oxide produc-
tion.27,28 Whether UA is a bystander, a partner or an
initiator of the metabolic syndrome cannot be answered
from the results of this cross-sectional study; a prospec-
tive study is needed to clarify their interrelationships.
This study had several limitations. First, the data
analysis was restricted due to the cross-sectional design
of the study. To confirm an interdependence of changes
in the risk factor components of metabolic syndrome
and serum UA level, a prospective study is needed.
Second, other confounding factors affecting UA, such
as alcohol consumption, the use of diuretics, physical
activity, and a diet habitually high in purines, were not
considered in this study. Since alcohol consumption is
significantly associated with elevated UA,31 there may
be some statistical bias due to misclassification. Finally,
the cohort was restricted to staff in a medical center,
so the results in this study may not be applicable to
the general population of Taiwan.
From our study, serum UA level increased as the
number of components of the metabolic syndrome in-
creased. Subjects with abnormal TG, WC, HDL-C and
BP had higher UA, in decreasing order of influence,
compared to subjects with normal levels. Elevated
UA was not noted in the abnormal fasting blood glu-
cose group compared to the group with normal levels.
Although UA had a strong association with metabolic
syndrome, a prospective study is warranted to deter-
mine if the prevention or treatment of hyperuricemia
affects the development of metabolic syndrome.
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